About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker ARGX · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 13, 2026A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants…
NCT07638566 · Chronic Inflammatory Demyelinating Polyradiculoneuropathy,…
Empasiprubart IV
ARGX
argenx
Phase 2/3Withdrawn
was not yet recruiting
0Apr 2028Registry ↗
Nov 9, 2026A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
NCT07091630 · Chronic Inflammatory Demyelinating Polyneuropathy, CIDP
Empasiprubart IV, Placebo IV
ARGX
argenx
Phase 3Recruiting160Oct 7, 2027Registry ↗
Nov 5, 2026A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations…
NCT06078553 · Congenital Myasthenic Syndrome
ARGX
argenx
—Active, not recruiting
was recruiting
152Sep 2027Registry ↗
Nov 4, 2026ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart…
NCT07673627 · AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthe…
Empasiprubart IV, Placebo IV
ARGX
argenx
Phase 2Recruiting40Oct 2027Registry ↗
Nov 4, 2026A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis
NCT06284954 · Dermatomyositis, Myositis
Empasiprubart IV, Placebo IV
ARGX
argenx
Phase 2Active, not recruiting3Nov 2026Registry ↗
Nov 4, 2026A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy
NCT05988073 · Multifocal Motor Neuropathy
ARGX
argenx
—Active, not recruiting413Dec 31, 2028Registry ↗
Nov 4, 2026A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod i…
NCT04280718 · Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Efgartigimod PH20 SC
ARGX
argenx
Phase 2Active, not recruiting229Apr 30, 2027Registry ↗
Nov 3, 2026A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves…
NCT07596849 · Graves Disease
efgartigimod PH20 SC, Placebo PH20 SC
ARGX
argenx
Phase 3Recruiting230Jun 2028Registry ↗
Nov 3, 2026A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves…
NCT07570316 · Graves' Disease, Graves Disease
Efgartigimod PH20 SC, Placebo PH20 SC
ARGX
argenx
Phase 3Recruiting230Jun 2028Registry ↗
Nov 3, 2026Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study
NCT07264426 · Chronic Inflammatory Demyelinating Polyradiculoneuropathy,…
Efgartigimod PH20 SC
ARGX
argenx
—Recruiting200Oct 2029Registry ↗
Nov 3, 2026A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
NCT06920004 · Chronic Inflammatory Demyelinating Polyneuropathy, CIDP
empasiprubart, IVIg
ARGX
argenx
Phase 3Recruiting218Sep 2027Registry ↗
Nov 3, 2026Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Admini…
NCT05374590 · Generalized Myasthenia Gravis, gMG
Efgartigimod IV or Efgartigimod PH20 SC
ARGX
argenx
Phase 2/3Enrolling by invitation12Sep 2029Registry ↗
Oct 29, 2026Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intraven…
NCT04833894 · Generalized Myasthenia Gravis
Efgartigimod IV
ARGX
argenx
Phase 2/3Active, not recruiting
was recruiting
15Mar 2027Registry ↗
Oct 28, 2026A Study of Empasiprubart as Add-On Therapy to IVIg in Adult Participants With Guillain-Barré Syndro…
NCT07821762 · Guillain-Barré Syndrome (GBS)
Empasiprubart IV, Empasiprubart Placebo IV
ARGX
argenx
Phase 2Not yet recruiting63Jan 2028Registry ↗
Oct 27, 2026A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With…
NCT07773727 · Immunoglobulin A Nephropathy (IgAN)
ARGX-121, Placebo
ARGX
argenx
Phase 2Recruiting120Oct 29, 2029Registry ↗
Oct 26, 2026ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple…
NCT07294170 · Myasthenia Gravis, MG
Efgartigimod IV, Empasiprubart IV
ARGX
argenx
—Recruiting70Mar 7, 2028Registry ↗
Oct 19, 2026A Study to Assess Efficacy and Safety of Adimanebart in Adult and Pediatric Participants With DOK7-…
NCT07746089 · Congenital Myasthenic Syndrome, CMS
Adimanebart IV, Placebo IV
ARGX
argenx
Phase 3Not yet recruiting105Oct 2030Registry ↗
Oct 19, 2026A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Pati…
NCT04812925 · Primary Immune Thrombocytopenia
efgartigimod PH20 SC
ARGX
argenx
Phase 3Active, not recruiting173Oct 2027Registry ↗
Oct 16, 2026A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic…
NCT07194850 · Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia
Efgartigimod IV, Placebo IV
ARGX
argenx
Phase 2/3Recruiting24Oct 2028Registry ↗
Oct 16, 2026A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
NCT06655155 · Systemic Sclerosis (SSc)
Efgartigimod PH20 SC, Placebo PH20 SC
ARGX
argenx
Phase 2Active, not recruiting87Mar 2027Registry ↗
Oct 16, 2026A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod i…
NCT05979441 · Myositis, Active Idiopathic Inflammatory Myopathy
Efgartigimod PH20 SC
ARGX
argenx
Phase 3Enrolling by invitation240Sep 2028Registry ↗
Oct 14, 2026A Study to Assess the Bioequivalence of Efgartigimod PH20 SC Between Autoinjector and Prefilled Syr…
NCT07782775 · Healthy Volunteer, Healthy Adult Participants
Efgartigimod PH20 SC via PFS, Efgartigimod PH20 SC via AI
ARGX
argenx
Phase 1Completed32Sep 23, 2026Registry ↗
Oct 14, 2026ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function
NCT05907096 · Delayed Graft Function
ARGX-117, Placebo
ARGX
argenx
Phase 2Active, not recruiting103Oct 16, 2025Registry ↗
Oct 8, 2026A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intra…
NCT07287982 · Spinal Muscular Atrophy (SMA)
ARGX-119 IV, Placebo IV
ARGX
argenx
Phase 2Recruiting60May 28, 2029Registry ↗
Sep 28, 2026A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalize…
NCT06392386 · Generalized Myasthenia Gravis
Efgartigimod PH20 SC
ARGX
argenx
Phase 2/3Recruiting12Sep 2027Registry ↗
Sep 24, 2026A Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Mult…
NCT07610564 · Multifocal Motor Neuropathy (MMN)
Empasiprubart IV
ARGX
argenx
Phase 1Recruiting60Feb 1, 2028Registry ↗
Sep 24, 2026ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV…
NCT07284420 · AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthe…
Efgartigimod IV, Empasiprubart IV
ARGX
argenx
Phase 2Recruiting70Mar 7, 2028Registry ↗
Sep 22, 2026A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In…
NCT07583641 · Autoimmune Encephalitis (AE)
Efgartigimod PH20 (ARGX-113) SC, Placebo PH20 SC
ARGX
argenx
Phase 2Not yet recruiting170Jul 2030Registry ↗
Sep 22, 2026A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Mo…
NCT06742190 · Multifocal Motor Neuropathy (MMN), MMN
Empasiprubart, IVIG (Intravenous Immunoglobulin)
ARGX
argenx
Phase 3Active, not recruiting154Sep 2026Registry ↗
Sep 21, 2026A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With A…
NCT05523167 · Active Idiopathic Inflammatory Myopathy, Myositis
EFG PH20 SC, PBO
ARGX
argenx
Phase 2/3Completed265Jul 2, 2026Registry ↗
Sep 15, 2026A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT06441682 · Amyotrophic Lateral Sclerosis
ARGX-119, Placebo
ARGX
argenx
Phase 2Terminated60Aug 12, 2026Registry ↗
Aug 12, 2026A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated S…
NCT07760818 · Sjogrens Disease, Primary Sjögren's Syndrome Painful Sensor…
efgartigimod PH20 SC, Placebo PH20 SC
ARGX
argenx
Phase 2Not yet recruiting75Jul 28, 2028Registry ↗
Aug 10, 2026A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholi…
NCT06298552 · Generalized Myasthenia Gravis, gMG
Efgartigimod IV, Placebo IV
ARGX
argenx
Phase 3Active, not recruiting119Jun 30, 2025Registry ↗
Jul 24, 2026A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7…
NCT06436742 · Congenital Myasthenic Syndrome, CMS
ARGX-119, Placebo
ARGX
argenx
Phase 1Active, not recruiting15Aug 24, 2027Registry ↗
Jul 2, 2026A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Grav…
NCT06558279 · Myasthenia Gravis, Ocular
Efgartigimod PH20 SC, Placebo PH20 SC
ARGX
argenx
Phase 3Active, not recruiting141Jan 12, 2026Registry ↗
Jul 2, 2026A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe…
NCT06503731 · Antibody-mediated Rejection
Efgartigimod PH20 SC - prefilled syringe, Placebo PH20 SC -…
ARGX
argenx
Phase 2Active, not recruiting33Nov 2027Registry ↗
Jun 29, 2026A Study to Assess the Absolute Bioavailability and How Adimanebart SC Moves Through the Body in Hea…
NCT07673601 · Healthy Volunteers (HV), Healthy Volunteer
Adimanebart IV, Adimanebart SC - formulation A
ARGX
argenx
Phase 1Recruiting52Dec 2026Registry ↗
May 28, 2026A Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered With an Autoinjecto…
NCT07612020 · Healthy Volunteers
empasiprubart SC AI, empasiprubart IV
ARGX
argenx
Phase 1Recruiting130Mar 2027Registry ↗
May 27, 2026An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigim…
NCT04980495 · Generalized Myasthenia Gravis, MG - Myasthenia Gravis
Efgartigimod IV
ARGX
argenx
Phase 3Completed69Aug 24, 2023Registry ↗
May 19, 2026A Study to Evaluate the Impact of Efgartigimod on Overall Disease Experience of People Suffering Fr…
NCT07595653 · Generalized Myasthenia Gravis (gMG), gMG
ARGX
argenx
—Recruiting100Nov 2027Registry ↗
May 8, 2026A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacody…
NCT05225675 · Multifocal Motor Neuropathy
ARGX-117, Placebo
ARGX
argenx
Phase 2Completed54Jun 4, 2024Registry ↗
May 1, 2026A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Imm…
NCT06544499 · Primary Immune Thrombocytopenia (ITP)
Efgartigimod IV, Placebo IV
ARGX
argenx
Phase 3Recruiting69Jun 2028Registry ↗
Apr 23, 2026A Study to Assess the Safety of ARGX-213 in Healthy Volunteers
NCT06968338 · Healthy Volunteers
ARGX-213, Placebo
ARGX
argenx
Phase 1Completed88Mar 20, 2026Registry ↗
Apr 16, 2026A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome
NCT06684847 · Primary Sjogrens Disease
Efgartigimod PH20 SC, Placebo PH20 SC
ARGX
argenx
Phase 3Active, not recruiting631Jul 2027Registry ↗
Apr 6, 2026A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC
NCT06637072 · Chronic Inflammatory Demyelinating Polyneuropathy
Efgartigimod PH20 SC
ARGX
argenx
Phase 4Completed23Feb 19, 2026Registry ↗
Mar 24, 2026Pre-Approval Access for Efgartigimod PH20 SC in Adults With Chronic Inflammatory Demyelinating Poly…
NCT04777734 · Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), C…
Efgartigimod PH20 SC
ARGX
argenx
—Available——Registry ↗
Mar 16, 2026A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.
NCT06307626 · Thyroid Eye Disease
Efgartigimod PH20 SC, Placebo PH20 SC
ARGX
argenx
Phase 3Terminated105Dec 15, 2025Registry ↗
Mar 16, 2026A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease
NCT06307613 · Thyroid Eye Disease
Efgartigimod PH20 SC, Placebo PH20 SC
ARGX
argenx
Phase 3Terminated102Dec 15, 2025Registry ↗
Mar 16, 2026A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary…
NCT04225156 · Primary Immune Thrombocytopenia
efgartigimod
ARGX
argenx
Phase 3Completed101Mar 11, 2026Registry ↗
Mar 11, 2026A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics,…
NCT05405361 · Multifocal Motor Neuropathy (MMN)
ARGX-117, Placebo
ARGX
argenx
Phase 2Active, not recruiting51Sep 30, 2029Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:22 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances